WO2001092476A3 - In vitro-gewebetestsystem - Google Patents

In vitro-gewebetestsystem Download PDF

Info

Publication number
WO2001092476A3
WO2001092476A3 PCT/EP2001/006072 EP0106072W WO0192476A3 WO 2001092476 A3 WO2001092476 A3 WO 2001092476A3 EP 0106072 W EP0106072 W EP 0106072W WO 0192476 A3 WO0192476 A3 WO 0192476A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
methods
tissue test
test system
analyzing
Prior art date
Application number
PCT/EP2001/006072
Other languages
English (en)
French (fr)
Other versions
WO2001092476A2 (de
Inventor
Christoph Dieterich
Steffen Rupp
Michaela Noll
Thomas Graeve
Original Assignee
Fraunhofer Ges Forschung
Christoph Dieterich
Steffen Rupp
Michaela Noll
Thomas Graeve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10026789A external-priority patent/DE10026789B4/de
Priority claimed from DE10062626A external-priority patent/DE10062626B4/de
Application filed by Fraunhofer Ges Forschung, Christoph Dieterich, Steffen Rupp, Michaela Noll, Thomas Graeve filed Critical Fraunhofer Ges Forschung
Priority to CA002410946A priority Critical patent/CA2410946A1/en
Priority to JP2002500670A priority patent/JP2004500855A/ja
Priority to US10/296,965 priority patent/US20040023907A1/en
Priority to AU69041/01A priority patent/AU6904101A/en
Priority to EP01947324A priority patent/EP1290144A2/de
Publication of WO2001092476A2 publication Critical patent/WO2001092476A2/de
Publication of WO2001092476A3 publication Critical patent/WO2001092476A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues
    • C12N2503/06—Screening or testing on artificial skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Die vorliegende Erfindung betrifft Mittel und Verfahren zur Analyse und Diagnose von durch pathogene und/oder parasitäre Mikroorganismen hervorgerufenen menschlichen oder tierischen Infektionen, Mittel und Verfahren zur Analyse und Diagnose von entarteten oder gentechnisch veränderten menschlichen oder tierischen Zellen sowie Mittel und Verfahren zur Untersuchung und Testung von Antiinfektiva und Arzneimitteln gegen Tumore sowie dreidimensionale in vitro-Organ- und Gewebetestmodelle, insbesondere von für Infektionen anfälligen Geweben, wie Darm, Haut, Cornea, Trachea und Schleimhäuten.
PCT/EP2001/006072 2000-05-31 2001-05-29 In vitro-gewebetestsystem WO2001092476A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002410946A CA2410946A1 (en) 2000-05-31 2001-05-29 In vitro tissue test system
JP2002500670A JP2004500855A (ja) 2000-05-31 2001-05-29 感染モデル
US10/296,965 US20040023907A1 (en) 2000-05-31 2001-05-29 Infection model
AU69041/01A AU6904101A (en) 2000-05-31 2001-05-29 Infection model
EP01947324A EP1290144A2 (de) 2000-05-31 2001-05-29 In vitro-gewebetestsystem

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10026789.0 2000-05-31
DE10026789A DE10026789B4 (de) 2000-05-31 2000-05-31 Knorpelersatz und Verfahren zu dessen Herstellung
DE10062626A DE10062626B4 (de) 2000-05-31 2000-12-15 Infektionsmodelle
DE10062626.2 2000-12-15

Publications (2)

Publication Number Publication Date
WO2001092476A2 WO2001092476A2 (de) 2001-12-06
WO2001092476A3 true WO2001092476A3 (de) 2002-11-07

Family

ID=26005891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/006072 WO2001092476A2 (de) 2000-05-31 2001-05-29 In vitro-gewebetestsystem

Country Status (6)

Country Link
US (1) US20040023907A1 (de)
EP (1) EP1290144A2 (de)
JP (1) JP2004500855A (de)
AU (1) AU6904101A (de)
CA (1) CA2410946A1 (de)
WO (1) WO2001092476A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
DE102010023156B4 (de) * 2010-06-02 2012-07-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. In vitro-Testsystem für virale Infektionen
WO2016013544A1 (ja) 2014-07-23 2016-01-28 国立研究開発法人物質・材料研究機構 高速応答・高感度乾湿応答センサー
CN206391052U (zh) * 2016-04-20 2017-08-11 珐博进(中国)医药技术开发有限公司 制备胶原蛋白眼角膜的装置
WO2018089743A1 (en) * 2016-11-10 2018-05-17 Organovo, Inc. Engineered intestinal tissue and uses thereof
US11856664B2 (en) * 2017-02-14 2023-12-26 National Institute For Materials Science Method and system for preventing dew condensation and light scattering due to dew condensation
CN114107172A (zh) * 2021-11-12 2022-03-01 上海市农业科学院 一种构建非感染性胃黏膜损伤细胞模型的方法及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016010A1 (en) * 1990-04-24 1991-10-31 Mark Eisenberg Composite living skin equivalents
WO1996009372A1 (en) * 1994-09-23 1996-03-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Artificial organ culture system
WO1997041208A1 (en) * 1996-04-26 1997-11-06 Case Western Reserve University Skin regeneration using mesenchymal stem cells
EP0851227A1 (de) * 1996-12-24 1998-07-01 L'oreal Verfahren zur Bewertung der durch UV-induzierten Hautbeschädigung
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5945101A (en) * 1993-03-17 1999-08-31 Berg; Richard A. Skin model system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485096A (en) * 1982-02-26 1984-11-27 Massachusetts Institute Of Technology Tissue-equivalent and method for preparation thereof
US5266480A (en) * 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4835102A (en) * 1987-03-31 1989-05-30 Eugene Bell Tissue equivalent test systems
US4996154A (en) * 1989-05-04 1991-02-26 Millipore Corporation Method for growing cellular tissue
IL95429A (en) * 1989-09-15 1997-09-30 Organogenesis Living tissue equivalents comprising hydrated collagen lattice and a collagen gel and their production

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
WO1991016010A1 (en) * 1990-04-24 1991-10-31 Mark Eisenberg Composite living skin equivalents
US5945101A (en) * 1993-03-17 1999-08-31 Berg; Richard A. Skin model system
WO1996009372A1 (en) * 1994-09-23 1996-03-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Artificial organ culture system
WO1997041208A1 (en) * 1996-04-26 1997-11-06 Case Western Reserve University Skin regeneration using mesenchymal stem cells
EP0851227A1 (de) * 1996-12-24 1998-07-01 L'oreal Verfahren zur Bewertung der durch UV-induzierten Hautbeschädigung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUSCO A C ET AL: "Penetration of Schistosoma mansoni cercariae into a living skin equivalent.", JOURNAL OF PARASITOLOGY, vol. 79, no. 3, 1993, pages 444 - 448, XP001064264 *

Also Published As

Publication number Publication date
AU6904101A (en) 2001-12-11
EP1290144A2 (de) 2003-03-12
WO2001092476A2 (de) 2001-12-06
JP2004500855A (ja) 2004-01-15
US20040023907A1 (en) 2004-02-05
CA2410946A1 (en) 2002-11-29

Similar Documents

Publication Publication Date Title
CN102245765B (zh) 细胞移植
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
WO2005030083A3 (en) Methods and products which utilize n-acyl-l-aspartic acid
TNSN07290A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
WO2002032292A3 (en) Methods for development and use of diagnostic and therapeutic agents
WO2001028496A3 (en) Device and method for improved diagnosis and treatment of cancer
WO2002040634A3 (en) Expression miniarrays and uses thereof
MXPA02011142A (es) Plataforma de nanodispositivo multifuncional.
BR0103256A (pt) Utilização de substâncias bioquìmicas para uma composição para a prevenção e tratamento de condições de saúde causadas por constrição de células de músculo liso em órgãos do corpo humano
WO2001038303A3 (fr) Analogues de la vitamine d
WO2007120252A3 (en) Soluble human m-csf receptor and uses thereof
WO2006127842A3 (en) Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease
WO2001092476A3 (de) In vitro-gewebetestsystem
BR0010314A (pt) Solução aquosa de conservação de tecidos e órgãos
CA2392168A1 (fr) Analogues de la vitamine d
AU9363398A (en) Hepatitis c receptor protein cd81
WO2004100998A3 (en) Compositions and methods for non-invasive imaging of soluble beta-amyloid
Çolakoğlu et al. Correlation between endoscopic and histopathological findings in dogs with chronic gastritis
WO2002046221A3 (en) Human protein differentially expressed in alzheimer's disease's brain
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
CA2435320A1 (en) Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
EP1202973A4 (de) Herstellung von verbindungen zur bestimmung der hypoxie
AU2002352054A1 (en) "in vitro" diagnostic method for diseases affecting human or animal tissues
WO2005115105A3 (en) Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001947324

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2410946

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001947324

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10296965

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001947324

Country of ref document: EP